A Phase II Trial to Assess the Efficacy of Efavirenz in Metastatic Patients With Androgen-independent Prostate Cancer.

Trial Profile

A Phase II Trial to Assess the Efficacy of Efavirenz in Metastatic Patients With Androgen-independent Prostate Cancer.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Efavirenz (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Acronyms FAVE
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 29 Jun 2012 Bristol-Myers Squibb added as associations as reported by European Clinical Trials Database.
    • 17 Mar 2012 Planned end date changed from 1 Dec 2009 to 4 Aug 2011 as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top